Related Experiment Videos
[Prolonged neuromuscular block with mivacurium]
M M Rodríguez-González1, C Arribas-Carrión, C Torre-Aznar
1Servicio de Anestesiología y Reanimación, Hospital Universitario de Canarias, Santa Cruz de Tenerife.
Revista Espanola De Anestesiologia Y Reanimacion
|January 10, 1998
Summary
A patient experienced prolonged neuromuscular block exceeding 8 hours after receiving mivacurium due to being homozygous for the atypical butyrylcholinesterase gene. This case highlights the critical need for vigilant neuromuscular monitoring in such scenarios.
Area of Science:
- Anesthesiology
- Pharmacogenetics
- Neuromuscular Pharmacology
Background:
- Mivacurium is a common neuromuscular blocking agent used in anesthesia.
- Genetic variations in butyrylcholinesterase can affect drug metabolism.
- Atypical butyrylcholinesterase is associated with prolonged responses to certain muscle relaxants.
Observation:
- A patient presented with an unusually long duration of neuromuscular blockade (over 8 hours) following mivacurium administration.
- Genetic testing revealed the patient was homozygous for the atypical butyrylcholinesterase gene variant.
- Standard reversal agents were ineffective in shortening the blockade duration.
Findings:
- Homozygosity for the atypical butyrylcholinesterase gene significantly impairs mivacurium metabolism.
- This genetic profile leads to profound and prolonged neuromuscular blockade.
- Neuromuscular monitoring is essential for managing such cases.
Implications:
- Clinicians must consider genetic factors when administering mivacurium.
- Prolonged neuromuscular block requires careful patient monitoring and supportive care.
- This case underscores the importance of pharmacogenetic screening for optimizing anesthetic drug administration and patient safety.